Latest Insider Transactions at Altimmune, Inc. (ALT)
This section provides a real-time view of insider transactions for Altimmune, Inc. (ALT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Altimmune, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Altimmune, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2023
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,658
-3.11%
|
$99,554
$13.78 P/Share
|
|
Feb 01
2023
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,546
+6.3%
|
-
|
|
Feb 01
2023
|
Matthew Scott Harris Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,183
-10.87%
|
$28,379
$13.78 P/Share
|
|
Feb 01
2023
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+23.49%
|
-
|
|
Feb 01
2023
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,183
-13.12%
|
$28,379
$13.78 P/Share
|
|
Feb 01
2023
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+27.04%
|
-
|
|
Jan 31
2023
|
Vipin K Garg President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,938
+0.84%
|
$19,380
$10.21 P/Share
|
|
Jan 31
2023
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,296
+8.52%
|
$12,960
$10.21 P/Share
|
|
Jan 31
2023
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,436
+12.06%
|
$14,360
$10.21 P/Share
|
|
Jan 31
2023
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,172
+8.89%
|
$11,720
$10.21 P/Share
|
|
Dec 31
2022
|
Richard I Eisenstadt Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,028
-21.84%
|
$48,448
$16.45 P/Share
|
|
Dec 31
2022
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+47.41%
|
-
|
|
Dec 22
2022
|
Wayne Pisano Director |
SELL
Open market or private sale
|
Direct |
20,000
-70.18%
|
$300,000
$15.01 P/Share
|
|
Dec 22
2022
|
Wayne Pisano Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+41.24%
|
$40,000
$2.6 P/Share
|
|
Nov 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.3%
|
$27,063
$9.95 P/Share
|
|
Nov 18
2022
|
David Drutz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
139
+0.69%
|
$278
$2.4 P/Share
|
|
Oct 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.29%
|
$36,084
$12.77 P/Share
|
|
Sep 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,008
-1.27%
|
$36,096
$12.77 P/Share
|
|
Aug 31
2022
|
Vipin K Garg President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-7.79%
|
$400,000
$20.02 P/Share
|
|
Aug 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.16%
|
$54,126
$18.94 P/Share
|
|
Aug 12
2022
|
John Gill Director |
SELL
Open market or private sale
|
Direct |
2,714
-49.48%
|
$40,710
$15.0 P/Share
|
|
Aug 12
2022
|
Vipin K Garg President and CEO |
SELL
Open market or private sale
|
Direct |
15,000
-5.46%
|
$225,000
$15.06 P/Share
|
|
Jul 31
2022
|
Matthew Scott Harris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,076
+7.86%
|
$6,456
$6.86 P/Share
|
|
Jul 31
2022
|
M Scot Roberts Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
732
+7.49%
|
$4,392
$6.86 P/Share
|
|
Jul 31
2022
|
Richard I Eisenstadt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,366
+50.0%
|
$8,196
$6.86 P/Share
|
|
Jul 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.08%
|
$36,084
$12.01 P/Share
|
|
Jul 05
2022
|
M Scot Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,182
-55.08%
|
$122,184
$12.0 P/Share
|
|
Jul 05
2022
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
787
+4.08%
|
$1,574
$2.95 P/Share
|
|
Jul 01
2022
|
M Scot Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
26,982
-60.39%
|
$323,784
$12.0 P/Share
|
|
Jul 01
2022
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,982
+24.78%
|
$53,964
$2.78 P/Share
|
|
Jun 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.07%
|
$33,077
$11.7 P/Share
|
|
Jun 29
2022
|
M Scot Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,462
-23.58%
|
$65,544
$12.0 P/Share
|
|
Jun 29
2022
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,462
+19.08%
|
$10,924
$2.6 P/Share
|
|
Jun 27
2022
|
Diane Jorkasky Director |
SELL
Open market or private sale
|
Direct |
17,610
-100.0%
|
$193,710
$11.75 P/Share
|
|
Jun 27
2022
|
Diane Jorkasky Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,610
+50.0%
|
$52,830
$3.15 P/Share
|
|
Jun 27
2022
|
M Scot Roberts Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
37,352
-67.85%
|
$448,224
$12.0 P/Share
|
|
Jun 27
2022
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,352
+27.38%
|
$74,704
$2.26 P/Share
|
|
Jun 20
2022
|
Klaus Schafer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
279
+1.01%
|
$558
$2.4 P/Share
|
|
Jun 15
2022
|
David Drutz Director |
BUY
Open market or private purchase
|
Direct |
1,000
+4.76%
|
$8,000
$8.0 P/Share
|
|
May 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,008
-1.06%
|
$15,040
$5.03 P/Share
|
|
May 24
2022
|
David Drutz Director |
BUY
Open market or private purchase
|
Direct |
1,200
+5.94%
|
$4,800
$4.5 P/Share
|
|
Apr 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,008
-1.05%
|
$12,032
$4.52 P/Share
|
|
Mar 30
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.04%
|
$18,042
$6.05 P/Share
|
|
Feb 28
2022
|
Matthew Scott Harris Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
30,000
-72.21%
|
$210,000
$7.52 P/Share
|
|
Feb 28
2022
|
Matthew Scott Harris Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+41.93%
|
$30,000
$1.92 P/Share
|
|
Feb 28
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,007
-1.03%
|
$21,049
$7.41 P/Share
|
|
Feb 01
2022
|
M Scot Roberts Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,183
-10.98%
|
$15,281
$7.98 P/Share
|
|
Feb 01
2022
|
M Scot Roberts Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,166
+23.67%
|
-
|
|
Feb 01
2022
|
Vipin K Garg President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,655
-2.55%
|
$53,585
$7.98 P/Share
|
|
Feb 01
2022
|
Vipin K Garg President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,545
+5.22%
|
-
|